• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Define Ventures Appoints Bruce Broussard as Venture Partner

    10/22/24 9:00:00 AM ET
    $EVH
    $HIMS
    $HUM
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care
    Get the next $EVH alert in real time by email

    The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation

    SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companies. 

    Bruce is a seasoned healthcare executive and multi-time CEO, having held executive leadership positions across multiple corners of the ecosystem. Prior to joining Define, Bruce was president and CEO of Humana for over a dozen years. Under his leadership, Bruce led a strategic shift towards expanding the company into an integrated model with a growing care delivery focus. Bruce also held several roles at McKesson Specialty Health including CEO, CFO, President, and Chairman of the Board. He currently serves on the Humana Foundation Board, is Chair of the Board of Directors of the Trust for the National Mall, and is a board member for HP Inc. and One Call.

    "Bruce's extensive background and proven track record in leading healthcare organizations of all sizes makes him uniquely qualified to guide the next generation of health tech innovators," said Lynne Chou O'Keefe, founder and managing partner at Define Ventures. "Having had the privilege to closely partner with Bruce for the past decade, I am confident his decision to join our team will sharpen our investing theses, accelerate our partner companies' growth, strengthen our relationships with large healthcare organizations, and ultimately create a lasting impact on the broader health tech community."

    Bruce is joining a team that pulls the full weight of its network and expertise to play offense and drive results, including securing early customers, shaping commercial strategies, and building high-performing teams. As venture partner, Bruce will leverage his experience driving transformative change within complex healthcare organizations to help Define founders to navigate industry challenges and scale their innovations effectively. His perspective will also strengthen Define's close partnerships with its coalition of large health systems, health plans, employers, and life sciences companies, half of which are customers of Define partner companies.

    "What excites me the most about this role is the opportunity to work with brilliant, innovative entrepreneurs at the earliest stages of their journey," Broussard said. "Being able to see groundbreaking approaches from the start, and having the chance to shape products and help scale and bring them to market is truly invigorating. Ultimately, I chose to work with Define because I believe this firm is uniquely positioned and capable of driving real transformation in healthcare. The strong, trustworthy relationship we've built over the years has shown me that Define's vision aligns perfectly with my own. Together, I believe we can make significant strides in creating a healthcare system that's more efficient, more accessible, and more focused on keeping people healthy."

    Bruce's decision to join Define Ventures stems from his belief that the firm is uniquely positioned and capable of transforming healthcare. He has built a strong and trustworthy relationship with Define over the past several years, including first-hand experience in incubating and spinning out Cohere Health from Humana. This collaborative history underscores the alignment between Bruce's vision for healthcare innovation and Define's strategic approach.

    Define Ventures has $800 million in assets under management and partners with companies at the seed, series A and series B stages. The firm attracts leading health tech entrepreneurs with its high conviction approach, partnering with over two dozen companies including Hims & Hers (NYSE:HIMS) and Unite Us. This announcement follows Frank Williams, co-founder and former CEO of Evolent (NYSE:EVH) joining Define as venture partner earlier this year.

    To learn more about Define Ventures, visit www.definevc.com.

    About Define Ventures

    Define Ventures is one of the largest funds focused on early-stage health tech companies. With $800 AUM, we take a high conviction approach in partnering with companies at the earliest stages. We believe the future of healthcare will be defined who bring together a deep understanding of the healthcare ecosystem paired with a technology-driven mindset. Our team was built in this vision, bringing together founders and investors who built category-defining companies and delivered $23 billion in exit value, including Livongo (LVGO), Evolent (NYSE:EVH), and Hims & Hers (NYSE:HIMS).

    Cision View original content:https://www.prnewswire.com/news-releases/define-ventures-appoints-bruce-broussard-as-venture-partner-302282546.html

    SOURCE Define Ventures

    Get the next $EVH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who has joined Define Ventures as a venture partner, and what is his background?

      Bruce Broussard, the former CEO of Humana, has joined Define Ventures as a venture partner to drive transformative change in healthcare and support early-stage health tech companies.

    • What is Define Ventures' focus and how much capital do they manage?

      Define Ventures focuses on early-stage health tech companies and has $800 million in assets under management (AUM). They partner with companies typically at the seed, series A, and series B stages.

    • Why has Bruce Broussard chosen to work with Define Ventures?

      Broussard believes Define Ventures is uniquely positioned to drive real transformation in healthcare, based on his strong relationship with the firm and shared vision for healthcare innovation.

    • What role will Bruce Broussard play at Define Ventures?

      Broussard will leverage his extensive experience in healthcare to guide founders through challenges, helping them scale their innovations and strengthen partnerships with large healthcare organizations.

    • Which companies has Define Ventures partnered with, showcasing their investment strategy?

      Define Ventures has partnered with notable companies in the health tech space, including Hims & Hers and Unite Us, highlighting their investment strategy focused on impactful entrepreneurs.

    Recent Analyst Ratings for
    $EVH
    $HIMS
    $HUM

    CompanyDatePrice TargetRatingAnalyst
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Evolent Health Inc
    $EVH
    2/25/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Hims & Hers Health Inc.
    $HIMS
    2/24/2026Buy → Neutral
    BTIG Research
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Hims & Hers Health Inc.
    $HIMS
    1/12/2026$33.00In-line
    Evercore ISI
    More analyst ratings

    $EVH
    $HIMS
    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hims & Hers Health from Underperform to Neutral and set a new price target of $23.00

    3/10/26 8:37:14 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Needham with a new price target

    Needham upgraded Hims & Hers Health from Hold to Buy and set a new price target of $30.00

    3/9/26 11:28:34 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    SEC Filings

    View All

    Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - HUMANA INC (0000049071) (Filer)

    3/9/26 4:22:23 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form DEFR14A filed by Humana Inc.

    DEFR14A - HUMANA INC (0000049071) (Filer)

    3/6/26 5:31:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Humana Inc.

    424B5 - HUMANA INC (0000049071) (Filer)

    3/6/26 4:33:29 PM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HIMS
    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Blackley Seth covered exercise/tax liability with 51,326 shares and was granted 58,921 shares, increasing direct ownership by 0.92% to 836,962 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 6:02:31 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    General Counsel Weinberg Jonathan was granted 4,910 shares and covered exercise/tax liability with 14,577 shares, decreasing direct ownership by 4% to 244,512 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 5:58:37 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph covered exercise/tax liability with 50,030 shares and was granted 39,281 shares, decreasing direct ownership by 2% to 423,022 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 5:53:20 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HIMS
    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    5/16/25 4:48:13 PM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HIMS
    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers

    The program debuts with Prenuvo and Eight Sleep, providing discounts on advanced diagnostics and sleep technology Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make comprehensive, holistic care more accessible and affordable for subscribers. "True health doesn't happen in a vacuum.

    3/10/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Humana Completes Aggregate $1.0 Billion Fixed-to-Fixed Rate Junior Subordinated Notes Offering

    Humana Inc. (the "company") (NYSE:HUM) announced today the completion of its public offering of $1.0 billion in aggregate principal amount of fixed-to-fixed rate junior subordinated notes due 2056, at 6.625 percent of the principal amount (the "Junior Subordinated Notes Offering"). The company expects net proceeds from the Junior Subordinated Notes Offering will be approximately $986 million after deducting underwriters' discounts and estimated offering expenses. The company intends to use the net proceeds from the Junior Subordinated Notes Offering for general corporate purposes, which may include the repayment of existing indebtedness, including borrowings under its commercial paper pro

    3/9/26 5:00:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    Hims & Hers Announces Strategic Shift for US Weight Loss Business

    Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s Hims & Hers Health, Inc. (NYSE:HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company's approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims & Hers will become t

    3/9/26 8:30:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Humana Announces Insurance Leadership Transition

    George Renaudin to Retire as Insurance Segment President by Q3 2026 Aaron Martin to Join as President of Medicare Advantage and Insurance Segment President Successor John Barger to Succeed Martin as President of Medicare Advantage Humana Inc. (NYSE:HUM) today announced that George Renaudin, Insurance Segment President and member of Humana's Enterprise Leadership Team, will retire by Q3 2026 following a successful 29-year career at the company. During this period, Renaudin played a pivotal role in establishing and growing Humana's Medicare Advantage and Medicaid programs, helping to build them into high-performing businesses and assembling a strong insurance leadership team. "George has co

    12/16/25 8:05:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Financials

    Live finance-specific insights

    View All

    Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025.Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model. We believe our total forecasted revenue growth of approximat

    2/24/26 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Humana Board Declares Payment of Quarterly Dividend to Stockholders

    Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 24, 2026 to stockholders of record as of the close of business on March 27, 2026. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

    2/19/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HIMS
    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care